Ilsung Is Co., Ltd. (KRX:003120)
South Korea
· Delayed Price · Currency is KRW 23,450
-300 (-1.26%)
Last updated: Dec 4, 2025, 9:00 AM KST
Ilsung Is Revenue
Ilsung Is had revenue of 16.76B KRW in the quarter ending September 30, 2025, a decrease of -11.87%. This brings the company's revenue in the last twelve months to 66.51B, down -10.33% year-over-year. In the year 2024, Ilsung Is had annual revenue of 69.02B, down -11.58%.
Revenue (ttm)
66.51B
Revenue Growth
-10.33%
P/S Ratio
2.44
Revenue / Employee
n/a
Employees
n/a
Market Cap
162.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 69.02B | -9.03B | -11.58% |
| Dec 31, 2023 | 78.05B | 16.81B | 27.44% |
| Dec 31, 2022 | 61.25B | 19.16B | 45.52% |
| Dec 31, 2021 | 42.09B | 1.49B | 3.67% |
| Dec 31, 2020 | 40.60B | -7.81B | -16.13% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,504.84B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| ABL Bio | 88.44B |
| SK Biopharmaceuticals | 675.41B |
| Yuhan | 2,136.67B |
| LigaChem Biosciences | 159.27B |
| Peptron | 6.19B |